Journal article
Phase I/II Trial of the Safety and Efficacy of AE-941 (Neovastat®) in the Treatment of Non–Small-Cell Lung Cancer
Abstract
AE-941 (Neovastat), an antiangiogenic component extracted from cartilage, selectively competes for the binding of vascular endothelial growth factor to its receptor, inhibits matrix metalloproteinases, stimulates tissue plasminogen activator enzymatic activities, and induces apoptotic activities in endothelial cells. A phase I/II study was conducted to obtain information on its safety and efficacy in patients with advanced cancer refractory to …
Authors
Latreille J; Batist G; Laberge F; Champagne P; Croteau D; Falardeau P; Levinton C; Hariton C; Evans WK; Dupont E
Journal
Clinical Lung Cancer, Vol. 4, No. 4, pp. 231–236
Publisher
Elsevier
Publication Date
January 2003
DOI
10.3816/clc.2003.n.003
ISSN
1525-7304